We are enclosing herewith the following: a. Audited Financial Results for the Financial Year ended March 31, 2026, as per format prescribed under Regulation 33 of Securities Exchange Board ....
PGHL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 10.9 pts more than Nifty Microcap 250 and 10.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Procter & Gamble Health Ltd reported strong full-year results for FY 2025-26 (12 months). Revenue from operations grew to ₹1,40,797 lakhs and net profit reached ₹32,691 lakhs, compared to the prior 9-month period (FY 2024-25) which had revenue of ₹93,417 lakhs and PAT of ₹23,441 lakhs. EPS for the year stood at ₹196.94 per share. The company also received an unmodified (clean) audit opinion from Haribhakti & Co. LLP. The Board recommended a final dividend of ₹45 per equity share, which together with an interim dividend of ₹160 per share makes the total dividend ₹205 per share for FY 2025-26. Note: The company changed its financial year from June to March, making the previous year's figures for only 9 months.
Positive signals for shareholders: strong profit growth, clean audit, and robust dividend payout. The change in financial year-end means direct year-on-year comparison requires adjustment for the 9-month vs 12-month period difference.